Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability of Donepezil With Solifenacin in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Next Previous
Trial Profile

Safety and Tolerability of Donepezil With Solifenacin in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil/solifenacin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Chase Pharmaceuticals

    • Most Recent Events

    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
    • 25 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top